Investor Presentation

53 Investor presentation First six months of 2022 ONWARDS 1 met its primary endpoint and demonstrated superior HbA1c reduction compared to insulin glargine U100 Superior change in HbA1c from baseline over time 52 weeks Time since randomisation (weeks) • Inclusion criteria T2D treated with OADs* + GLP-1 s.c. 10 18 0.0 -0.4 Change from baseline (%) -0.8 -1.2 26 36 46 52 52* • Age ≥ 18 years, HbA1c 7.0-11.0%, BMI ≤ 40 kg/m² H Κ KH HH Novo NordiskⓇ Endpoints: Once-weekly insulin icodec achieved a superior reduction in estimated HbA1c of -1.55% compared to -1.35% for insulin glargine U100 (ETD:-0.19%) Superior time in range for insulin icodec vs insulin glargine U100 broadly equal to one additional hour in range per day -1.35% Safety: -1.55% -1.6 -2.0 Once-weekly insulin icodec Note: Overall baseline HbA1c of 8.5% Once-daily insulin glargine U100 No statistically significant difference in estimated rates of severe or clinically significant hypoglycaemia events Insulin icodec appeared to have a safe and well-tolerated profile *Lines are based on observed data where the value denoted after 52 weeks is estimated mean value derived based on multiple imputation ETD: Estimate treatment difference

View entire presentation